Longeveron (LGVN) Biotech Showcase 2025 summary

Company overview and product pipeline

• Focuses on cell therapies for aging-related and life-threatening conditions, with a lead product, Lomecel-B, targeting three indications: aging-related frailty, Alzheimer's disease, and hypoplastic left heart syndrome (HLHS).

• Completed five clinical trials across these indications, with a sixth (phase II-B for HLHS) nearing completion.

• Holds multiple FDA designations, including orphan drug, rare pediatric disease, fast-track, and RMAT for different indications.

• Lomecel-B is an allogeneic, donor-derived mesenchymal stem cell therapy produced from healthy adult volunteers.

• Maintains a strong management team and is financially positioned to fund operations through early 2026.

Clinical trial highlights and regulatory progress

• HLHS phase I trial showed 100% five-year survival without transplant, compared to 80% in historical controls.

• Phase II-B HLHS trial is over 80% enrolled, conducted at top U.S. academic centers, and is co-sponsored by NIH/NHLBI.

• FDA confirmed the HLHS phase II-B trial as pivotal for full approval, agreeing to endpoints and CMC plans; BLA filing targeted for 2026.

• Alzheimer's phase II-A trial met primary and secondary endpoints, showing safety and cognitive improvement, with 49% less brain atrophy decline versus placebo.

• Alzheimer's program received RMAT and fast-track designations; partnership sought for further development.

Market opportunity and strategic focus

• U.S. market opportunities: Alzheimer's ($10B), aging-related frailty ($4–8B), HLHS ($1B).

• Prioritizing HLHS and Alzheimer's programs due to market size and regulatory progress.

• Aging-related frailty program showed significant improvement in six-minute walk test but is deprioritized for now.

• Holds a priority review voucher for rare pediatric disease, available upon approval.

• 14.8 million shares outstanding and $23 million in cash and equivalents.